논문 목록
14건 · 최신순-
How to define failure of intradetrusor injections of botulinum toxin A for neurogenic detrusor overactivity.
[INTRODUCTION] Neurogenic detrusor overactivity (NDO) has a major impact on patients' quality of life and can lead to upper urinary tract complications. Intradetrusor botulinum toxin type A injections are administered as second-line treatme…
-
Comparison of quality of life after bladder augmentation in patients previously treated with intradetrusor botulinum toxin A for neurogenic detrusor overactivity.
[PURPOSE] To compare the quality of life (QoL) in the same patients first treated with botulinum toxin A (BTA) injections for neurogenic detrusor overactivity (NDO) and then with bladder augmentation (BA). [METHOD] Retrospective study of p…
-
[Guidelines on the urological management of the adult patient with spinal dysraphism (spina bifida)].
[INTRODUCTION] Improved life expectancy and prenatal screening have changed the demographics of spina bifida (spinal dysraphism) which has presently become a disease of adulthood. Urinary disorders affect almost all patients with spinal dys…
-
[Bladder augmentation in the era of botulinum toxin: Indications and results].
[AIM] To determine the surgical indication and results of bladder augmentation (BA) during the last decade in a neurourology center in the era of intradetrusor botulinum toxin injection. [MATERIAL] We conducted a retrospective study that i…
-
[Intradetrusor injections of botulinum toxin A to treat urinary incontinence due to bladder overactivity during idiopathic Parkinson's disease].
[INTRODUCTION] During idiopathic Parkinson's disease (IPD), lower urinary tract symptoms and dysfunctions are frequent, dominated by overactive bladder and detrusor overactivity (OAB, DO). Intradetrusor Injection (IDI) of Botulinum Toxin A …
-
[French Association of Urology. COVID-19: Recommendations for functional urology].
[AIM] The management of urology patient is currently disrupted by the COVID-19 epidemic. In the field of functional urology, there are clinical situations with a high risk of complication if management is delayed and a great heterogeneity o…
-
Botulinum Toxin Type A Injection After Failure of Augmentation Enterocystoplasty Performed for Neurogenic Detrusor Overactivity: Preliminary Results of a Salvage Strategy. The ENTEROTOX Study.
[OBJECTIVE] To evaluate the clinical efficacy, urodynamic effect and safety of Botulinum Toxin A (BTXA) injections after failure of augmentation enterocystoplasty (AE) performed for neurogenic detrusor overactivity. [PATIENTS AND METHODS] …
-
Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.
[AIMS] To assess the outcomes of switching to a different brand of botulinum toxin A (BTA, from Botox® to Dysport®) in case of failure of intradetrusor injections (IDI) of Botox® in the treatment of neurogenic detrusor overactivity (NDO). …
-
Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a randomized clinical trial.
[OBJECTIVE] To explore efficacy and safety of Botulinum Neurotoxin Type A (BoNT-A) prostatic injection in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperperplasia. [MATERIALS AND METHODS] A phase 3 multicent…
-
Intradetrusor Injections of Botulinum Toxin Type A in Children With Spina Bifida: A Multicenter Study.
[OBJECTIVE] To assess the effectiveness of intradetrusor injections of botulinum toxin type A (IDBTX-A) in children with spina bifida. [METHODS] All patients aged less than 16 years old who underwent IDBTX-A between 2002 and 2016 at 6 inst…
-
Intradetrusor Injections of Botulinum Toxin A in Adults with Spinal Dysraphism.
[PURPOSE] The aim of the current study was to determine the outcomes of botulinum toxin A intradetrusor injections in adult patients with spina bifida. [MATERIALS AND METHODS] All patients with spinal dysraphism who underwent intradetrusor…
-
Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study.
[AIMS] To present final efficacy/safety results from a prospective, long-term extension trial of onabotulinumtoxinA for urinary incontinence (UI) due to neurogenic detrusor overactivity (NDO); patients received treatment for up to 4 years. …
-
Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study.
[AIMS] Assess the efficacy and safety of abobotulinumtoxinA (Dysport®) in adult patients with neurogenic detrusor overactivity (NDO). [METHODS] This Phase IIa, international, multicentre, double-blind, randomised, placebo controlled, pilot…
-
[Definition of botulinum toxin failure in neurogenic detrusor overactivity: Preliminary results of the DETOX survey].
[OBJECTIVE] There is currently no guideline regarding the management of neurogenic detrusor overactivity (NDO) refractory to intra-detrusor botulinum toxin injections. The primary objective of the present study was to find a consensus defin…